Biosimilars as antivirals: opportunities and challenges

Anan S. Jarab,Shrouq R Abu Heshmeh,Ahmad Z. Al Meslamani
DOI: https://doi.org/10.1080/14787210.2024.2313064
2024-02-03
Expert Review of Anti-infective Therapy
Abstract:KEYWORDS: Antiviral drugs are specifically designed to treat viral infections, but they face various obstacles that pose significant challenges. In contrast to antibiotics, the range of antiviral drugs remains very limited. This scarcity arises because viruses represent much more complex targets than bacteria. Viruses reside inside our cells and depend on our proteins to meet their requirements, making them elusive targets. Therefore, eliminating the virus without causing harm to the host cell poses an enormous challenge [ Citation 1 ]. The recent coronavirus pandemic (COVID-19) is a prime example of the urgent need for effective antiviral drugs. COVID-19, caused by the SARS-CoV-2 virus, rapidly evolved into a global health crisis, illustrating how contagious viruses can quickly lead to a pandemic. The impact of COVID-19 underscores the importance of developing new antivirals that are both effective and accessible. Developing these drugs from scratch is an expensive and time-consuming process, and the high cost of many antivirals limits their affordability, highlighting the need for more cost-effective options. Another critical issue in antiviral therapy is the development of resistance, where pathogens undergo genetic and protein modifications, becoming unaffected by existing drugs, posing a significant challenge [ Citation 1 ].
pharmacology & pharmacy,infectious diseases,microbiology
What problem does this paper attempt to address?